Comparative Pharmacology
Head-to-head clinical analysis: ALOMIDE versus GASTROCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOMIDE versus GASTROCROM.
ALOMIDE vs GASTROCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lodoxamide stabilizes mast cells by preventing antigen-induced release of histamine and other inflammatory mediators (e.g., SRS-A) from the mast cell, possibly by inhibiting calcium influx.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
1 to 2 drops in each affected eye four times daily (every 6 hours).
200 mg orally four times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours. Clinically, this short half-life supports frequent dosing for sustained ocular effects.
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Primarily renal excretion; approximately 50-60% of the dose is excreted unchanged in urine within 24 hours. Fecal elimination accounts for less than 10%. Minor biliary excretion.
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer